Top Story

Six important FDA updates

October 28, 2016

The FDA has announced several decisions related to hematology and oncology treatments in the past 2 weeks.

HemOnc Today presents six FDA actions that may be relevant to your practice.

In the Journals Plus

Tumor genome testing may reduce overtreatment of early-stage breast cancer

October 27, 2016
The use of the 21-gene recurrence score assay improved treatment decision-making and personalized the use of chemotherapy for women with early-stage breast cancer…

American Cancer Society, Weight Watchers join forces to support breast cancer survivors

October 27, 2016
The American Cancer Society, in collaboration with Weight Watchers International Inc., launched a new initiative designed to help breast cancer survivors combat the…
In the Journals Plus

Left-sided tumor location reduces colon cancer mortality risk

October 27, 2016
Patients diagnosed with left-sided colon cancer appeared to have nearly a 20% reduced risk for death compared with those with right-sided tumors, according to results of…
In the Journals

More than 25% of internal medicine residents say patient responsibility ends at discharge

October 27, 2016
Internal medicine residents are uncertain about the duration of their responsibilities for patients who have been discharged, according to survey results published in…
More News Headlines »

The Patient with Myelofibrosis

No commercial support for this activity.

Myelofibrosis is caused by abnormal stem cells in the bone marrow that cause the uncontrolled production of mature…
More »
Meeting News Coverage

VIDEO: Combination therapy with PD-L1, PARP inhibitors appears effective in patients with ovarian, breast cancer

September 8, 2016
More »

Management of Multiple Myeloma: Using Emerging Therapies with ASCT

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Spectrum Pharmaceuticals, Inc.; and Takeda Oncology.

Multiple myeloma management has undergone profound changes in the past few decades, this is largely due to advances in…
More »
Current Issues
View the Current Issue
HemOnc Today